A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Grifols

Status and phase: Completed; Phase 2; Phase 1

Conditions: Acute Ischemic Stroke

Treatments: Biological: Plasmin (Human)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01014975

2010-019760-36 (EudraCT Number)

T05018-1001

Details and patient eligibility

About

This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot component, fibrin. In this study, Plasmin (Human) is administered locally through a catheter to the clot within 9 hours of the stroke onset. Three doses of Plasmin (Human) (20 mg, 40 mg, and 80 mg) are being tested in 3 different groups of patients. Patients are monitored by imaging of the affected artery and functional testing.

Full description

This is a Phase 1/2a, open-label, multi-center, sequential dose escalation, safety study of Plasmin (Human) in acute ischemic stroke caused by middle cerebral artery occlusion documented by arteriography. Plasmin (Human) will be administered through a catheter into the thrombus within 9 hours of stroke onset. Approximately sixty-one (61) patients will be enrolled and will receive Plasmin (Human). The objectives of this study are to determine the safety of escalating doses of Plasmin (Human) and to determine the proportion of patients with treatment success, defined as partial or full recanalization.

Enrollment: 40 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. 18 to 85 years of age
2. Male or female
3. New focal, potentially disabling neurologic deficit clinically localized to the MCA distribution
4. Intra-arterial therapy with Plasmin completed within 9 hours of stroke onset
5. A National Institutes of Health Stroke Scale score ≥ 4 and ≤ 25

Exclusion criteria

1. Intracranial procedures or intracranial or systemic bleeding within the last year
2. Intracranial neoplasm (except meningioma), septic embolism, or unsecured aneurysm
3. Active bleeding
4. History of stroke in previous 6 weeks
5. Uncontrolled hypertension
6. Renal disease or renal dialysis
7. Treatment with any plasminogen activator within the last 48 hrs.
8. Therapy with a Glycoprotein IIb/IIIa inhibitor in 5 days prior to study enrollment or at any time during study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 3 patient groups

20 mg Plasmin (Human)

Experimental group

Description:

20 mg of Plasmin (Human)

Treatment:

Biological: Plasmin (Human)

Biological: Plasmin (Human)

Biological: Plasmin (Human)

40 mg Plasmin (Human)

Experimental group

Description:

40 mg of Plasmin (Human)

Treatment:

Biological: Plasmin (Human)

Biological: Plasmin (Human)

Biological: Plasmin (Human)

80 mg Plasmin (Human)

Experimental group

Description:

80 mg of Plasmin (Human)

Treatment:

Biological: Plasmin (Human)

Biological: Plasmin (Human)

Biological: Plasmin (Human)